A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

Serena Di Cosimo, José Baselga, Ludmila Prudkin et al.|Journal of Clinical Oncology|2010

Cited by 67